U.S. markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.38%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.07%)
     
  • BTC-USD

    35,964.97
    +297.76 (+0.83%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Hypertention Diagnostics Updating Information to all Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

TORONTO, ON / ACCESSWIRE / June 17, 2020 / Hypertention Diagnostics, Inc.(HDII) ("Hypertension Diagnostics" or the "Company") CEO Liangjian Peng said he received a lot of inquiries about the Company future development. Mr. Peng thanks all inquired people, and he said the company is working on to remove the STOP sign as soon as possible, and switch to Current Pink before implementing any M&A issues.

About Hypertension Diagnostics Inc.

Hypertension Diagnostics, Inc. is a public company currently trading on the OTC Markets (HDII). HDII was originally incorporated in Minnesota.

Safe Harbor Statement Information in this press release may contain 'forward-looking statements.' Statements describing objectives or goals or the Company's future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Hypertension Diagnostics Inc.'s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Hypertension Diagnostic Inc. periodic reports filed with the regulatory authorities.

CONTACT:

Jeff Peng
Liangjianpeng2018@gmail.com

SOURCE: Hypertension Diagnostics Inc.



View source version on accesswire.com:
https://www.accesswire.com/594203/Hypertention-Diagnostics-Updating-Information-to-all-Shareholders